UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                                 WASHINGTON D.C.

                                   FORM 10-QSB

 [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange
                Act of 1934, For the Quarter Ended June 30, 2006

    [_] Transitional Report Pursuant to Section 13 or 15(d) of the Securities
                              Exchange Act of 1934

                          Commission File No. 000-28459

                      ADVANCED PLANT PHARMACEUTICALS, INC.

             (Exact name of Registrant as specified in its charter)


               Delaware                              59-2762023
         -------------------                     -------------------
   (State  of other jurisdiction       (I.R.S. Employer Identification Number)
of  incorporation  or  organization)


                 43 West 33rd Street, New York, New York 10001
                 ---------------------------------------------
                     Address of principal executive offices

        Registrant's telephone number, including area code: 212-695-3334

      Indicate by check mark whether the issuer (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities and Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the
issuer was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

                                 Yes [X] No [_]

      As of August 18, 2006, there were issued and outstanding 798,157,996,
shares of Common Stock, $.0007 par value per share.

      Transitional Small Business Disclosure Format Yes [X] No [_]

      Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act) Yes [_] No [X]


<PAGE>


                      ADVANCED PLANT PHARMACEUTICALS, INC.

                                      INDEX
                                      -----

                                                                           PAGE
                                                                          NUMBER
                                                                          ------
PART I.  FINANCIAL INFORMATION
------------------------------

Item 1.  Condensed financial statements     (unaudited)

         Condensed Balance sheets as of June 30, 2006 (Unaudited)
           and December 31, 2005                                             3

         Condensed Statements of operations (Unaudited) for the
            three months and six months ended ended June 30, 2006
            and 2005                                                         4

         Condensed Statements of cash flows (Unaudited) for the six
            months ended June 30, 2006 and 2005                              5

         Notes to the condensed financial statements                         7

Item 2.  Management's Discussion and Analysis of Financial
         Condition and Results of Operations                                11

Item 3.  Controls and Procedures                                            15

PART II. OTHER INFORMATION                                                  16
---------------------------

SIGNATURES                                                                  17


<PAGE>


                                     PART I

ITEM 1. CONDENSED FINANCIAL STATEMENTS

Item 1. Financial Statements

              ADVANCED PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES

                           CONSOLIDATED BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                                   June 30,     December 31,
                                                                                     2006           2005
                                                                                 ------------   ------------
                                                                                  Unaudited      (Restated)
                                     ASSETS
CURRENT ASSETS
<S>                                                                              <C>            <C>
   Cash                                                                          $      3,384   $     11,688
   Accounts receivable                                                                                 1,188
   Miscellaneous receivable                                                             5,000
   Prepaid expenses - officers                                                          9,882         31,550
                                                                                 ------------   ------------
           Total Current Assets                                                        18,266         44,426
OFFICE EQUIPMENT, net of accumulated depreciation of $3,500
    and $2,942, respectively                                                              853          1,411
OTHER ASSETS
   Goodwill                                                                            10,406         10,406
   Due from related company                                                            13,500          9,000
   Other assets                                                                         5,444          7,144
                                                                                 ------------   ------------
                                                                                       29,350         26,550
                                                                                 ------------   ------------
           Total Assets                                                          $     48,469   $     72,387
                                                                                 ============   ============

                    LIABILITIES AND STOCKHOLDERS' DEFICIENCY

CURRENT LIABILITIES
   Bank overdraft                                                                $      5,682   $      7,977
   Accounts payable                                                                   156,582        192,371
   Accrued expenses                                                                   358,567        229,794
   Accrued expenses - officers                                                      1,279,467      1,220,481
   Due to distributor
   Due to stockholder - asset acquisition                                           1,315,000      1,315,000
   Deposits to acquire common stock                                                    67,500
   Loans payable - stockholders                                                       374,643        369,290
                                                                                 ------------   ------------
           Total Current Liabilities                                                3,557,441      3,334,913

DEFERRED CREDIT                                                                     4,755,105      4,286,105

STOCKHOLDERS' DEFICIENCY
    Preferred stock, authorized 10,000,000 shares; $0.0007 par value; 5,000,000
        shares issued and outstanding at June 30, 2006 and
        December 31, 2005                                                               3,500          3,500
   Common stock, authorized 880,000,000
        shares; $0.0007 par value; 798,157,996
        shares issued and outstanding at June 30,
        2006 and December 31, 2005                                                    558,711        558,711
   Additional paid-in capital                                                      14,681,548     14,681,548
   Accumulated deficit                                                            (23,507,836)   (22,792,390)
                                                                                 ------------   ------------

   Total Stockholders' Deficiency                                                  (8,264,077)    (7,548,631)
                                                                                 ------------   ------------
           Total Liabilities and Stockholders' Deficiency                        $     48,469   $     72,387
                                                                                 ============   ============
</TABLE>

                 See accompanying notes to financial statements.


<PAGE>


              ADVANCED PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES

                CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

<TABLE>
<CAPTION>
                                            For the Three Months Ended      For the Six Months Ended
                                                      June 30,                      June 30,
                                            ---------------------------   ---------------------------
                                                2006           2005           2006           2005
                                            ------------   ------------   ------------   ------------

<S>                                         <C>            <C>            <C>            <C>
REVENUE - SALES                             $      2,575   $      3,799   $      4,551   $      5,929

COSTS AND EXPENSES
   Cost of goods sold                                               704                         1,826
   Salaries and consulting fees - officers       158,700        185,613        425,400        265,413
   Selling, general and administrative
      expenses                                   228,443        182,729        598,171        406,181
   Depreciation                                      279            280            558            559
                                            ------------   ------------   ------------   ------------

             Total Costs and Expenses            387,422        369,326      1,024,129        673,979
                                            ------------   ------------   ------------   ------------

NET OPERATING LOSS                              (384,847)      (365,527)    (1,019,578)      (668,050)

OTHER INCOME (EXPENSE)
   Gain on sale of investment                    308,300                       308,300
   Interest expense                                 (125)           (30)        (4,168)           (30)
                                            ------------   ------------   ------------   ------------

             Net Other Income (Expense)          308,175            (30)       304,132            (30)
                                            ------------   ------------   ------------   ------------

NET LOSS                                    $    (76,672)  $   (365,557)  $   (715,446)  $   (668,080)
                                            ============   ============   ============   ============

NET LOSS PER SHARE OF COMMON
   STOCK                                    $       (.00)  $       (.00)  $       (.00)  $       (.00)
                                            ============   ============   ============   ============

WEIGHTED AVERAGE NUMBER
    OF COMMON  SHARES
    OUTSTANDING
                                             798,157,996    794,685,469    798,157,996    787,351,366
                                            ============   ============   ============   ============
</TABLE>

                See accompanying notes to financial statements.


<PAGE>


              ADVANCED PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES

                CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

<TABLE>
<CAPTION>
                                                               For the Six Months Ended
                                                                       June 30,
                                                             ---------------------------
                                                                 2006           2005
                                                             ------------   ------------
CASH FLOWS FROM OPERATING ACTIVITIES
<S>                                                          <C>            <C>
   Net loss                                                  $   (715,446)  $   (668,080)
   Adjustments to reconcile net loss to cash flows
      used in operating activities
          Stock issued for services                               324,000        125,863
          Gain on sale of investment                             (308,300)
          Stock held for investment issued for services            72,000
          Depreciation expense                                        558            559
   Changes in assets and liabilities:
      Decrease in accounts receivable                               1,188            306
      Increase in inventory                                                       (1,137)
      Decrease (increase) in prepaid expenses - officers           21,668        (13,200)
      Decrease in due from related company                         (4,500)        (4,500)
      Decrease in accounts payable                                (35,789)        (4,334)
      Increase in accrued expenses                                128,773        132,463
      Increase in accrued expenses - officers                     226,986         97,966
                                                             ------------   ------------
        Net cash used in operating activities                    (288,862)      (334,094)

CASH FLOWS FROM INVESTING ACTIVITIES
   Cash paid for intangible assets                                                (5,579)
   Due from related parties                                        65,000
                                                             ------------   ------------
        Net cash provided by (used in) investing activities        65,000         (5,579)

CASH FLOWS FROM FINANCING ACTIVITIES
   Bank overdraft                                                  (2,295)         6,946
   Cash acquired in acquisition of subsidiary
   Loans payable - stockholders' - net                              5,353         20,650
   Increase in deposits                                            67,500        345,000
   Proceeds from issuance of Mazal common stock                   145,000
   Proceeds from issuance of common stock                                         56,500
                                                             ------------   ------------
        Net cash provided by financing activities                 215,558        429,096
                                                             ------------   ------------

        Net (decrease) increase in cash                            (8,304)        89,423

CASH AT BEGINNING OF PERIOD                                        11,688          1,045
                                                             ------------   ------------

CASH AT END OF PERIOD                                        $      3,384   $     90,468
                                                             ============   ============
</TABLE>

                See accompanying notes to financial statements.


<PAGE>


              ADVANCED PLANT PHARMACEUTICALS, INC AND SUBSIDIARIES

                CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)

<TABLE>
<CAPTION>
                                                                         For the Six Months Ended
                                                                                 June 30,
                                                                       ------------   ------------
                                                                           2006            2005
                                                                       ------------   ------------
<S>                                                                    <C>            <C>
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

   CASH PAID
      Interest                                                         $        475   $         30

   NON-CASH INVESTING AND FINANCING ACTIVITIES

      Issuance of common stock for services                                           $    125,863

      Issuance of preferred stock in payment of loans payable
        to stockholders                                                                     10,000

      Issuance of preferred stock in payment of accrued expenses
        to stockholders                                                                     10,000

      Purchase of intangible assets for loan payable to stockholder                         19,000

      Issuance of Mazal common stock for services classified as
        A deferred credit                                              $    324,000

      Miscellaneous receivable from sale of stock held for investment         5,000

      Issuance of stock held for investment in payment of accrued
        Expenses - officers                                                 168,000
</TABLE>

                See accompanying notes to financial statements.


<PAGE>


              ADVANCED PLANT PHARMACEUTICALS, INC AND SUBSIDIARIES

                          NOTES TO FINANCIAL STATEMENTS
                                  JUNE 30, 2006


NOTE A - CONDENSED FINANCIAL STATEMENTS

In the opinion of the Company, the accompanying unaudited condensed financial
statements include all adjustments (consisting only of normal recurring
accruals) which are necessary for a fair presentation of the results for the
periods presented. Certain information and footnote disclosure, normally
included in the financial statements prepared in accordance with generally
accepted accounting principles, have been condensed and omitted. The results of
operations for the three and six month periods ended June 30, 2006 are not
indicative of the results of operations for the year ended December 31, 2006.
The condensed financial statements should be read in conjunction with the
Company's financial statements included in its annual Form 10 KSB for the year
ended December 31, 2005.

NOTE B - STOCK WARRANTS

At June 30, 2006, the Company had outstanding warrants to purchase 7,000,000
shares of the Company's common stock at a price of $.03 per share. The warrants
are exercisable and expire at various dates through 2007.

NOTE C - COMMITMENTS AND CONTINGENCIES

The Company has employment agreements with nine employees and a consulting
contract with a key consultant, who are also stockholders of the Company and
Mazal Plant Pharmaceuticals, Inc. ("Mazal"). At June 30, 2006, the Company has a
total liability for accrued salaries and consulting expense to stockholders of
$1,139,201. There could be certain payroll tax liabilities owed to the IRS on
some of the payments for services to certain consultants that were paid in prior
years, pursuant to these employment agreements.

NOTE D - DEPOSITS TO ACQUIRE COMMON STOCK

The deposits to acquire common stock at June 30, 2006 in the amount of $67,500
represents deposits to acquire shares of Mazal common stock for which there are
no written agreements at the present time. The deposits are non-interest
bearing.

NOTE E - RELATED PARTIES STOCK AND ASSET TRANSACTIONS

On January 24, 2006, Mazal issued 200,000 shares of its common stock to a
consultant at $1.08 per share. The aggregate remuneration of $216,000 has been
treated as stock based compensation and expensed in the current period.

On January 25, 2006, Mazal issued 100,000 shares of its common stock to its
President at $1.08 per share. The aggregate remuneration of $108,000 has been
treated as stock based compensation and expensed in the current period.

On February 7, 2006, Mazal approved the issuance of 200,000 shares of its common
stock at $0.25 per share pursuant to a private placement. Mazal incurred $5,000
in expenses related to the private placement and realized $45,000.

On April 11, 2006, Mazal approved the issuance of 400,000 shares of its common
stock at $0.25 per share pursuant to a private placement realizing $100,000.


<PAGE>


              ADVANCED PLANT PHARMACEUTICALS, INC AND SUBSIDIARIES

                          NOTES TO FINANCIAL STATEMENTS
                                  JUNE 30, 2006


NOTE F - GAIN ON SALE OF INVESTMENT

The gain on sale of investment resulted from the sale of 500,000 shares of
common stock of Amazon Biotech, Inc., an affiliated company, for $70,000. The
Company received $65,000 and $5,000 is included in miscellaneous receivables.
The stock had a basis of $500.

The gain on sale of investment also includes the transfer of 1,200,000 shares of
common stock of Amazon Biotech, Inc., to three officers of the Company in
payment of accrued salaries - officers in the amount of $168,000 and
compensation in the amount of $72,000. The stock had a basis of $1,200.


NOTE G - GOING CONCERN

As reflected in the accompanying financial statements, the Company has current
liabilities in excess of current assets of $3,539,175, resulting in negative
working capital and an accumulated deficit of $23,507,836. Management is
presently seeking to raise permanent equity capital in the capital markets to
eliminate negative working capital and provide working capital. Failure to raise
equity capital or secure some other form of long-term debt arrangement will
cause the Company to further increase its negative working capital deficit and
could result in the Company having to curtail or cease operations. Additionally,
even if the Company does raise sufficient capital to support its operating
expenses and generate revenues, there can be no assurances that the revenue will
be sufficient to enable it to develop business to a level where it will generate
profits and cash flows from operations. These matters raise substantial doubt
about the Company's ability to continue as a going concern. However, the
accompanying financial statements have been prepared on a going concern basis,
which contemplates the realization of assets and satisfaction of liabilities in
the normal course of business. These financial statements do not include any
adjustments relating to the recovery of the recorded assets or the
classification of the liabilities that might be necessary should the Company be
unable to continue as a going concern.


NOTE H - SUBSEQUENT EVENTS

On July 25, 2006, the Company entered into an agreement of settlement and
release with its President and transferred 200,000 shares of common stock of
Amazon Biotech, Inc., held as an investment, as payment of $22,000 of accrued
salary.

On July 1, 2006, Mazal authorized the issuance of 244,000 shares of its common
stock for cash at $0.25 per share realizing $61,000.

On July 11, 2006, Mazal amended its 2005 Stock Compensation Plan to allow for
the issuance of 3,500,000 shares, an increase of 2,500,000 shares.

On July 17, 2006, Mazal entered into a consulting agreement whereby the
consultant is to introduce medical clinics and assist in the development of
clinical trials for Mazal for a term of one year. Either party may terminate the
contract with or without cause upon thirty days written notice. The agreement
calls for the issuance of 500,000 shares of Mazal common stock upon signing and
1,500,000 shares of Mazal common stock upon Mazal receiving a letter of intent
from a medical center that has previously performed clinical trials for a major
pharmaceutical company, to perform clinical trials at competitive rates, in
which at least one third (33%) of the payment shall be in shares of Mazal common
stock.


<PAGE>


              ADVANCED PLANT PHARMACEUTICALS, INC AND SUBSIDIARIES

                          NOTES TO FINANCIAL STATEMENTS
                                  JUNE 30, 2006


NOTE H - SUBSEQUENT EVENTS (CONTINUED)

On July 31, 2006, Mazal entered into an Interim Letter of Agreement for a Phase
I/II, double-blind, placebo and active-controlled, randomized, parallel-group
study to evaluate the safety and efficacy of MAHDL01 alone and as an adjunct to
statin therapy, versus placebo or statin therapy alone, in increasing HDL in
subjects with hypoalphalipoproteinemia who are maintaining a restricted diet.
The agreement calls for a minimum number of subjects of ten and a maximum of
four hundred. Mazal is responsible for all external direct trial expenses. The
consultant will receive $2,500 per subject who completes the study, where fifty
percent (50%) will be paid in cash and the remaining fifty percent (50%) will be
paid in shares of Mazal common stock.


<PAGE>


ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS

Background

Advanced Plant Pharmaceuticals, Inc. (the "Company") was incorporated in the
State of Delaware in 1986, under the name Ventra Management, Inc. On July 20,
1994, we amended our Certificate of Incorporation to change our name to Advanced
Plant Pharmaceuticals, Inc.

Description of Business

The Company continues to focus on the research and development of plant based
dietary supplements. In July 1999, the Company acquired exclusive rights and
interests to a thirteen-step process, which utilizes virtually all of the
nutrients found in plants to manufacture natural herbal dietary supplements. The
purchase price for the thirteen step process was 12,000,000 shares of common
stock of the Company. The shares were issued on February 13, 2001. Further, the
Company is required to issue an additional 6,000,000 shares of common stock when
marketing of the product commences. The Company intends to use this process to
manufacture products that it hopes to distribute worldwide through various sales
distribution contracts.

On February 28, 2000, the Company entered into an Asset Purchase Agreement with
Dr. Bielory to purchase his various allergy and nasal formulations. This
agreement was approved by the Board of Directors on September 6, 2000. Dr.
Bielory was granted a five year option to purchase an aggregate of 18,000,000
shares of the Company's common stock at an exercise price of $180.00. Dr.
Bielroy exercised an option for 12,000,000 shares in the first quarter of 2001.

Sinusol, being the formulation purchased from Dr. Bielory, is a generalized base
solution for the development of an extensive line of specialty products related
to allergy and sinus conditions. The ingredients include a mixture of gently
pH-balanced essential mineral oils that combat the various symptoms related to
allergies and sinus disorders, including congestions, irritated nasal mucosa and
bacterial and fungal infections. Specialized advanced formulations are being
reviewed for patent submission.

In addition to Sinusol, the Company is also currently marketing its Lo-Chol
product. Lo-Chol's formula is derived from the "whole plant" parts of six
selected plants that work in concert to help tip your lipid balance (good and
bad cholesterol) towards a more normal level. These six plants are
synergistically combined using a proprietary "whole plant technology" (a special
pharmaceutical-grade process) that delivers virtually all the natural
phyto-chemicals and active ingredients in the plants. Unlike almost all other
herbal supplements on the market, Lo-Chol does not contain any extracts.
Instead, it utilizes the entire part of a specific plant that is processed and
standardized to deliver optimum potency and nutritional benefits.

Recent Developments

In January 2004, the Company acquired a 44% interest in Amazing Nutritionals,
Inc., a development stage company, whereby APPI sold Amazing all of the rights,
title, patents, trademarks, processes and related items of LHM123 which is a
natural composition for the treatment of senile dementias in consideration for
3,300,000 shares of Amazing's common stock.

In December 2004, the Company acquired a 99% interest in Mazal Plant
Pharmaceuticals, Inc. ("Mazal"), a development stage company, whereby APPI sold
Mazal all of its rights relating to or connected with developing, manufacturing
and distributing of three of its products, plant based compositions designed to
treat elevated cholesterol, leukemia and Alzheimer's disease in consideration
for 7,000,000 shares of Mazal's common stock and a receivable of $50,000.

On June 6, 2005, the Company consummated the transactions contemplated by the
Share Exchange Agreement dated as of May 2005 (the "Share Exchange Agreement")
by and among the Company, Akid Corporation ("Akid") and James B. Wiegand.
Pursuant to the Share Exchange Agreement, the Company sold its entire ownership
interest in 7,000,000 shares of the common stock of Mazal to Akid. In exchange,
Akid agreed to issue to the Company 20,000,000 shares (the "Exchange Shares") of
Akid's common stock. Following the consummation of such share exchange, the
Company holds a majority of the issued and outstanding common shares of Akid,
and Akid holds a majority of the issued and outstanding common shares of Mazal.


<PAGE>


Akid issued to the Company 17,500,000 of the Exchange Shares at the closing, and
agreed to issue the remaining 2,500,000 of the Exchange Shares upon increasing
its authorized common stock from 20,000,000 shares to 40,000,000 shares. In
October 2005, Akid amended its Articles of Incorporation to change its name to
Mazal Plant Pharmaceuticals, Inc.

Results of Operations

Results of Operations - Three Months Ended June 30, 2006 Compared to the Three
Months Ended June 30, 2005.

Revenues

Revenues generated during the three months ended June 30, 2006, aggregated
$2,575, as compared to $3,799 for the three months ended June 30, 2005. The
decrease of $1,224 in revenues from the comparable period in the prior year is
primarily due to a decrease in marketing due to a lack of funding.

Costs of Goods Sold

Cost of Goods Sold for the three months ended June 30, 2006 aggregated $-0- as
compared to $704 for the three months ended June 30, 2005. The decrease for the
three months ended June 30, 2006 is the result of a decrease in sales of our
products.

Operating Expenses

Operating Expenses incurred for the three months ended June 30, 2006, aggregated
$387,422 as compared to $368,622 for three months ended June 30, 2005, which is
a decrease of $18,800. This decrease was primarily due to a decrease in the
issuance of stock for services and the payment of fees for officers and
consultants.

Net Loss and Loss Per Common Share

The net loss and the loss per common share was $76,672 and $.00 for the three
months ended June 30, 2006, as compared to net loss of $365,557 and $.00 for the
three months ended June 30, 2005. This decrease was due primarily to the
decrease in the issuance of stock for services and the payment of fees to
officers and consultants.

Liquidity and Capital Resources

At June 30, 2006, we had working capital deficit of $3,539,175 as compared with
$3,290,487 at December 31, 2005. The increase in the working capital deficit is
primarily the result of an increase in accrued expenses.

We have historically sustained our operations and funded our capital
requirements with the funds received from the sale of our products, loans
received from related parties and the sale of our securities. We will still need
additional investments in order to continue operations. Additional investments
are being sought, but we cannot guarantee that we will be able to obtain such
investments.

Financing transactions may include the issuance of equity or debt securities,
obtaining credit facilities, or other financing mechanisms. However, the trading
price of our common stock and the downturn in the U.S. stock and debt markets
could make it more difficult to obtain financing through the issuance of equity
or debt securities. Even if we are able to raise the funds required, it is
possible that we could incur unexpected costs and expenses, fail to collect
significant amounts owed to us, or experience unexpected cash requirements that
would force us to seek alternative financing. Further, if we issue additional
equity or debt securities, stockholders may experience additional dilution or
the new equity securities may have rights, preferences or privileges senior to
those of existing holders of our common stock. If additional financing is not
available or is not available on acceptable terms, we will have to curtail our
operations again.

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles
generally accepted in the United States requires management of the Company to
make assumptions, estimates and judgments that affect the amounts reported in
the financial statements, including the notes thereto, and related disclosures
of commitments and contingencies, if any. The Company considers its critical
accounting policies to be those that require the more significant judgments and
estimates in the preparation of the Company's financial statements, including
the following: valuation of inventories and intangible assets, valuation of
stock options and warrants, and valuation of all accrued liabilities including
payroll taxes and other contingent liabilities. Management relies on historical
experience and on other assumptions believed to be reasonable under the
circumstances in making its judgment and estimates. Actual results could differ
materially from those estimates.


<PAGE>


ITEM 3 - CONTROLS AND PROCEDURES

As of the end of the period covered by this report, we conducted an evaluation,
under the supervision and with the participation of our chief executive officer
and principal financial officer of our disclosure controls and procedures (as
defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act). Based upon
this evaluation, our chief executive officer and principal financial officer
concluded that our disclosure controls and procedures are effective to ensure
that information required to be disclosed by us in the reports that we file or
submit under the Exchange Act is recorded, processed, summarized and reported,
within the time periods specified in the Commission's rules and forms. There was
no change in our internal controls or in other factors that could affect these
controls during our last fiscal year that has materially affected, or is
reasonably likely to materially affect, our internal control over financial
reporting.


<PAGE>


                                     PART II

ITEM 1 - LEGAL PROCEEDINGS

From time to time, the Company is a party to litigation or other legal
proceedings that it considers to be a part of the ordinary course of its
business. The Company is not involved currently in legal proceedings that could
reasonably be expected to have a material adverse effect on its business,
prospects, financial condition or results of operations except as set forth
below. We may become involved in material legal proceedings in the future.

ITEM 2 - CHANGES IN SECURITIES

On January 24, 2006, Mazal Plant Pharmaceuticals, Inc. ("Mazal") issued 200,000
shares of its common stock to a consultant at $1.08 per share. The aggregate
remuneration of $216,000 has been treated as stock based compensation and
expensed in the current period.

On January 25, 2006, Mazal issued 100,000 shares of its common stock to its
President at $1.08 per share. The aggregate remuneration of $108,000 has been
treated as stock based compensation and expensed in the current period.

On February 7, 2006, Mazal approved the issuance of 200,000 shares of its common
stock at $0.25 per share pursuant to a private placement. Mazal incurred $5,000
in expenses related to the private placement and realized $45,000.

On April 11, 2006, Mazal approved the issuance of 400,000 shares of its common
stock at $0.25 per share pursuant to a private placement realizing $100,000.

The gain on sale of investment resulted from the sale of 500,000 shares of
common stock of Amazon Biotech, Inc., an affiliated company, for $70,000. The
Company received $65,000 and $5,000 is included in miscellaneous receivables.
The stock had a basis of $500.

The gain on sale of investment also includes the transfer of 1,200,000 shares of
common stock of Amazon Biotech, Inc., to three officers of the Company in
payment of accrued salaries - officers in the amount of $168,000 and
compensation in the amount of $72,000. The stock had a basis of $1,200.

On July 25, 2006, the Company entered into an agreement of settlement and
release with its President and transferred 200,000 shares of common stock of
Amazon Biotech, Inc., held as an investment, as payment of $22,000 of accrued
salary.

On July 1, 2006, Mazal authorized the issuance of 244,000 shares of its common
stock for cash at $0.25 per share realizing $61,000.

On July 11, 2006, Mazal amended its 2005 Stock Compensation Plan to allow for
the issuance of 3,500,000 shares, an increase of 2,500,000 shares.

On July 17, 2006, Mazal entered into a consulting agreement whereby the
consultant is to introduce medical clinics and assist in the development of
clinical trials for Mazal for a term of one year. Either party may terminate the
contract with or without cause upon thirty days written notice. The agreement
calls for the issuance of 500,000 shares of Mazal common stock upon signing and
1,500,000 shares of Mazal common stock upon Mazal receiving a letter of intent
from a medical center that has previously performed clinical trials for a major
pharmaceutical company, to perform clinical trials at competitive rates, in
which at least one third (33%) of the payment shall be in shares of Mazal common
stock.

ITEM 3 - DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None

ITEM 5 - OTHER INFORMATION

On July 31, 2006, Mazal entered into an Interim Letter of Agreement for a Phase
I/II, double-blind, placebo and active-controlled, randomized, parallel-group
study to evaluate the safety and efficacy of MAHDL01 alone and as an adjunct to
statin therapy, versus placebo or statin therapy alone, in increasing HDL in
subjects with hypoalphalipoproteinemia who are maintaining a restricted diet.
The agreement calls for a minimum number of subjects of ten and a maximum of
four hundred. Mazal is responsible for all external direct trial expenses. The
consultant will receive $2,500 per subject who completes the study, where fifty
percent (50%) will be paid in cash and the remaining fifty percent (50%) will be
paid in shares of Mazal common stock.


<PAGE>


ITEM 6. - EXHIBITS

      (a)Exhibits

      31.1  Certification of the Chief Executive Officer and Principal Financial
            Officer of Advanced Plant Pharmaceuticals, Inc. pursuant to Section
            302 of the Sarbanes-Oxley Act of 2002.

      32.1  Certification of the Chief Executive Officer and Principal Financial
            Officer of Advanced Plant Pharmaceuticals, Inc. pursuant to Section
            906 of the Sarbanes-Oxley Act of 2002.


<PAGE>


                                   SIGNATURES

      In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                      ADVANCED PLANT PHARMACEUTICALS, INC.


                      By:  /s/ David Lieberman
                          --------------------------------------------
                          David Lieberman, Chief Executive Officer and
                          Principal Financial Officer


Dated: August 21, 2006